The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Giredestrant shows promise despite missing primary goal
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Merck emphasized the broader significance of the findings
Subscribe To Our Newsletter & Stay Updated
